U.S. Stock Market Update: Windtree Therapeutics down 7.05%

U.S. Stock Market Midday Update Windtree Therapeutics fell 7.05%, with increased trading volume. Based on recent key news: On August 5, Windtree Therapeutics announced the interim analysis results of its Istaroxime Phase 2 study, with data supporting the advancement to a global Phase 3 clinical trial, but no new safety signals were found. The market reacted lukewarmly to the trial results, leading to a decline in stock price. On August 5, documents submitted by Windtree Therapeutics to the U.S. Securities and Exchange Commission showed that Andrew Albert Kucharchuk was appointed as a company director. Investors took a wait-and-see attitude towards the management changes, further exacerbating stock price volatility. On August 5, Windtree Therapeutics announced that board member Leanne Kelly resigned, and Andrew Kucharchuk took over as chairman of the audit committee. The management changes raised market concerns, leading to a drop in stock price. Stocks with High Trading Volume in the Industry Gilead Sciences rose 8.25%, with increased trading volume. Based on recent important news: On August 8, Gilead Sciences released its Q2 2025 financial report, showing a 4% year-over-year increase in product sales, reaching $6.9 billion, exceeding market expectations, and the stock price rose 5.92% in pre-market trading. On August 8, the company raised its full-year revenue and earnings guidance, expecting adjusted earnings per share to be between $7.95 and $8.25, higher than previously expected, with a positive market reaction. On August 8, analysts generally upgraded Gilead Sciences' rating, with Needham analysts raising their rating from hold to buy, setting a target price of $133, driving the stock price up. Forte Pharmaceuticals fell 1.87%, with increased trading volume. Based on recent important news: On August 6, Forte Pharmaceuticals' target price was lowered to 500 yuan, putting pressure on the stock price, which fell 1.87%. On August 5, analyst ratings for Forte Pharmaceuticals showed market concerns about its future performance, affecting stock price performance. On August 4, Forte Pharmaceuticals' VX-993 failed to meet primary endpoints in Phase 2 trials, leading to a significant drop in stock price. Natera rose 11.87%, with increased trading volume. Based on recent important news: On August 8, Natera reported record quarterly revenue and growth in Signatera sales, prompting an upward revision of annual revenue and gross margin guidance, with the stock price rising 11.87%. On August 8, Natera's short interest decreased by 41.44%, enhancing bullish sentiment towards the company's stock, further driving the stock price up On August 8th, JP Morgan and Bernstein raised the target price for Natera, reflecting the market's confidence in the company's future growth. Stocks ranked among the top in industry market capitalization AbbVie fell 0.40%, with increased trading volume. Based on recent important news: On August 5th, AbbVie acquired Gilgamesh Pharmaceuticals, expanding its presence in the mental disorder medication field, with a positive market reaction and a short-term rise in stock price. On August 5th, AbbVie raised its full-year guidance, although the market remains skeptical about the sustainability of growth, leading to stock price fluctuations. On August 8th, analysts' buy ratings for AbbVie were not as favorable as those for five other stocks, affecting investor confidence